Retatrutide
The triple-hormone agonist posting the biggest trial weight-loss numbers yet - still investigational. Education only.
Three hormones, record numbers.
Retatrutide adds a third target - glucagon - to the GIP/GLP-1 combination, and it is posting the largest trial weight-loss figures the field has seen. It is not approved or available outside trials; it is here because it is the compound everyone is asking about.
At a glance
Where the research focuses.
Weight management
The largest trial weight-loss numbers to date but investigational, not approved.
Liver fat / MASLD
Marked liver-fat reduction in phase-2 data.
Type 2 diabetes
Studied across the TRIUMPH phase-3 programme.
Sleep apnoea
Among the conditions under phase-3 investigation.
Adding the glucagon arm.
The third receptor, glucagon, adds direct fat-burning in the liver on top of the appetite and glucose effects of GIP/GLP-1 - which appears to push weight loss and liver-fat reduction beyond the dual drugs.
It is genuinely promising and genuinely unfinished: strong trial readouts, but not yet approved or available outside studies.
Strength of the evidence.
- Phase-2 and first phase-3 readouts strong
- Triple-agonist mechanism characterised
- Liver-fat and diabetes signals
- Cross-trial edge over dual agonists
- Not yet approved or available
- Long-term safety still being studied
How it works
Triple agonism
Engages GIP, GLP-1 and glucagon receptors.
CharacterisedGlucagon arm
Adds hepatic fat-burning to appetite effects.
MechanisticAppetite & glucose
GIP/GLP-1 cut appetite and improve glucose.
ClinicalSide effects
GI effects dose-related, as with other incretins.
Trial dataRetatrutide is in phase-3 trials and is not approved or sold anywhere outside those studies; an FDA submission is expected around 2026–2027. Apex does not sell it, and any 'research retatrutide' on the market is unverified and legally fraught. Information only.
- For research purposes only
- Not for human consumption
- Not FDA approved
- Consult a qualified professional